1 | Patients with suspected prostate cancer (e.g., high/rising PSA levels, abnormal digital rectal examination results) evaluated for targeted biopsy and detection of intraprostatic tumor | Rarely appropriate | 3 |
2 | Patients with very-low, low-, and favorable intermediate-risk prostate cancer | Rarely appropriate | 2 |
3 | Newly diagnosed unfavorable intermediate-, high-risk, or very-high-risk prostate cancer | Appropriate | 8 |
4 | Newly diagnosed unfavorable intermediate-, high-risk, or very-high-risk prostate cancer with negative/equivocal or oligometastatic disease on conventional imaging | Appropriate | 8 |
5 | Newly diagnosed prostate cancer with widespread metastatic disease on conventional imaging | May be appropriate | 4 |
6 | PSA persistence or PSA rise from undetectable level after radical prostatectomy | Appropriate | 9 |
7 | PSA rise above nadir after definitive radiotherapy | Appropriate | 9 |
8 | PSA rise after focal therapy of the primary tumor | May be appropriate | 5 |
9 | nmCRPC (M0) on conventional imaging | Appropriate | 7 |
10 | Posttreatment PSA rise in the mCRPC setting | May be appropriate | 6 |
11 | Evaluation of response to therapy | May be appropriate | 5 |